- Home
- PRME vs VTYX Comparison
PRME vs VTYX Comparison
Compare PRME & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- VTYX
- Stock Information
- Founded
- PRME 2019
- VTYX 2018
- Country
- PRME United States
- VTYX United States
- Employees
- PRME N/A
- VTYX N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- PRME Health Care
- VTYX Health Care
- Exchange
- PRME Nasdaq
- VTYX Nasdaq
- Market Cap
- PRME 191.7M
- VTYX 154.9M
- IPO Year
- PRME 2022
- VTYX 2021
- Fundamental
- Price
- PRME $2.71
- VTYX $2.07
- Analyst Decision
- PRME Buy
- VTYX Buy
- Analyst Count
- PRME 6
- VTYX 4
- Target Price
- PRME $9.38
- VTYX $11.33
- AVG Volume (30 Days)
- PRME 3.3M
- VTYX 2.2M
- Earning Date
- PRME 08-04-2025
- VTYX 08-07-2025
- Dividend Yield
- PRME N/A
- VTYX N/A
- EPS Growth
- PRME N/A
- VTYX N/A
- EPS
- PRME N/A
- VTYX N/A
- Revenue
- PRME $3,846,000.00
- VTYX N/A
- Revenue This Year
- PRME $104.12
- VTYX N/A
- Revenue Next Year
- PRME $196.78
- VTYX N/A
- P/E Ratio
- PRME N/A
- VTYX N/A
- Revenue Growth
- PRME 550.76
- VTYX N/A
- 52 Week Low
- PRME $1.11
- VTYX $0.78
- 52 Week High
- PRME $6.75
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- PRME 69.76
- VTYX 47.05
- Support Level
- PRME $1.56
- VTYX $2.05
- Resistance Level
- PRME $2.78
- VTYX $2.51
- Average True Range (ATR)
- PRME 0.26
- VTYX 0.20
- MACD
- PRME 0.08
- VTYX -0.07
- Stochastic Oscillator
- PRME 76.81
- VTYX 2.44
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.